Estrella Immunopharma, Inc.
ESLA
$0.64
$0.00-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.09% | -26.41% | -47.65% | -53.10% | -65.16% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.14% | 27.39% | 52.02% | -- | -37.18% |
| Change in Net Operating Assets | -104.54% | -25.58% | 1,269.00% | 209.07% | 173.67% |
| Cash from Operations | -134.91% | -107.12% | 76.63% | 86.10% | 75.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 533.09% | 12,981.76% | 2,918.87% | -- | -85.71% |
| Repurchase of Common Stock | 100.00% | 100.00% | 94.81% | 98.32% | 95.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,991.00% | -- | -- | 96.54% | 94.99% |
| Cash from Financing | 617.03% | 2,290.34% | 560.36% | 131.52% | -91.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.93% | 134.97% | 105.75% | 99.16% | -268.95% |